دورية أكاديمية
Long-term efficacy of high-frequency (10 kHz) spinal cord stimulation for the treatment of painful diabetic neuropathy: 24-Month results of a randomized controlled trial.
| العنوان: | Long-term efficacy of high-frequency (10 kHz) spinal cord stimulation for the treatment of painful diabetic neuropathy: 24-Month results of a randomized controlled trial. |
|---|---|
| المؤلفون: | Petersen EA; Department of Neurosurgery, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205, USA. Electronic address: EAPetersen@uams.edu., Stauss TG; Advanced Pain Management, 4131 W Loomis Rd Ste 300, Greenfield, WI 53221, USA., Scowcroft JA; Pain Management Associates, 200 NE Missouri Rd Ste 103, Lee's Summit, MO 64086, USA., Jaasma MJ; Nevro Corp, 1800 Bridge Pkwy, Redwood City, CA 94065, USA., Brooks ES; Nevro Corp, 1800 Bridge Pkwy, Redwood City, CA 94065, USA., Edgar DR; Commexus Ltd, Dunblane, Scotland, UK., White JL; AES Compass Orlando, 100 W Gore St, Orlando, FL 32806, USA., Sills SM; Touchstone Interventional Pain Center, 2925 Siskiyou Blvd, Medford, OR 97504, USA., Amirdelfan K; IPM Medical Group, 450 N Wiget Ln, Walnut Creek, CA 94598, USA., Guirguis MN; Ochsner Health System, 2820 Napoleon Ave, New Orleans, LA 70115, USA., Xu J; Department of Pain Management, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA., Yu C; Swedish Medical Center, 1101 Madison St, Seattle, WA 98104, USA., Nairizi A; Nevada Advanced Pain Specialists, 5578 Longley Ln, Reno, NV 89511, USA., Patterson DG; Nevada Advanced Pain Specialists, 5578 Longley Ln, Reno, NV 89511, USA., Tsoulfas KC; Advanced Pain Management, 4131 W Loomis Rd Ste 300, Greenfield, WI 53221, USA., Creamer MJ; Central Florida Pain Relief Centers, 100 W Gore St #500, Orlando, FL 32806, USA., Galan V; Pain Care, 1365 Rock Quarry Rd #301, Stockbridge, GA 30281, USA., Bundschu RH; Coastal Orthopedics and Sports Medicine, 8000 SR 64, Bradenton, FL 34212, USA., Mehta ND; Department of Anesthesiology, Weill Cornell Medical College, 240 East 59th Street, 2nd Floor, New York, NY 10022, USA., Sayed D; Department of Anesthesiology and Pain Medicine, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA., Lad SP; Department of Neurosurgery, Duke University, 40 Duke Medicine Cir, Durham, NC 27710, USA., DiBenedetto DJ; Boston PainCare, 85 1st Ave, Waltham, MA 02451, USA., Sethi KA; Department of Neurosurgery, United Health Services, 46 Harrison St, Johnson City, NY 13790, USA., Goree JH; Department of Anesthesiology, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205, USA., Bennett MT; Department of Neurosurgery, United Health Services, 46 Harrison St, Johnson City, NY 13790, USA., Harrison NJ; Ochsner Health System, 2820 Napoleon Ave, New Orleans, LA 70115, USA., Israel AF; Pain Management Associates, 200 NE Missouri Rd Ste 103, Lee's Summit, MO 64086, USA., Chang P; Pain Care, 1365 Rock Quarry Rd #301, Stockbridge, GA 30281, USA., Wu PW; Holy Cross Hospital, 5601 N Dixie Hwy #209, Fort Lauderdale, FL 33334, USA., Argoff CE; Department of Neurology, Albany Medical Center, 47 New Scotland Avenue, Albany, NY 12208, USA., Nasr CE; Division of Endocrinology, Department of Internal Medicine, The University of Arizona College of Medicine - Phoenix, 475 N 5th St, Phoenix, AZ 85004, USA., Taylor RS; MRC/CSO Social and Public Health Sciences Unit, Robertson Centre for Biostatistics, School of Health and Well Being, Clarice Pears Building, University of Glasgow, Glasgow, Scotland G12 8QQ, UK., Caraway DL; Nevro Corp, 1800 Bridge Pkwy, Redwood City, CA 94065, USA., Mekhail NA; Evidence-Based Pain Management Research, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA. |
| المصدر: | Diabetes research and clinical practice [Diabetes Res Clin Pract] 2023 Sep; Vol. 203, pp. 110865. Date of Electronic Publication: 2023 Aug 01. |
| نوع المنشور: | Randomized Controlled Trial; Multicenter Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8508335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8227 (Electronic) Linking ISSN: 01688227 NLM ISO Abbreviation: Diabetes Res Clin Pract Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1993- : Limerick : Elsevier Scientific Publishers Original Publication: Amsterdam : Elsevier Science Publishers B.V., c1985- |
| مواضيع طبية MeSH: | Spinal Cord Stimulation*/methods , Diabetic Neuropathies*/therapy , Diabetes Mellitus*, Humans ; Quality of Life ; Prospective Studies ; Pain ; Treatment Outcome |
| مستخلص: | Aims: To evaluate the long-term efficacy of high-frequency (10 kHz) spinal cord stimulation (SCS) for treating refractory painful diabetic neuropathy (PDN). Methods: The SENZA-PDN study was a prospective, multicenter, randomized controlled trial that compared conventional medical management (CMM) alone with 10 kHz SCS plus CMM (10 kHz SCS+CMM) in 216 patients with refractory PDN. After 6 months, participants with insufficient pain relief could cross over to the other treatment. In total, 142 patients with a 10 kHz SCS system were followed for 24 months, including 84 initial 10 kHz SCS+CMM recipients and 58 crossovers from CMM alone. Assessments included pain intensity, health-related quality of life (HRQoL), sleep, and neurological function. Investigators assessed neurological function via sensory, reflex, and motor tests. They identified a clinically meaningful improvement relative to the baseline assessment if there was a significant persistent improvement in neurological function that impacted the participant's well-being and was attributable to a neurological finding. Results: At 24 months, 10 kHz SCS reduced pain by a mean of 79.9% compared to baseline, with 90.1% of participants experiencing ≥50% pain relief. Participants had significantly improved HRQoL and sleep, and 65.7% demonstrated clinically meaningful neurological improvement. Five (3.2%) SCS systems were explanted due to infection. Conclusions: Over 24 months, 10 kHz SCS provided durable pain relief and significant improvements in HRQoL and sleep. Furthermore, the majority of participants demonstrated neurological improvement. These long-term data support 10 kHz SCS as a safe and highly effective therapy for PDN. Trial Registration: ClincalTrials.gov Identifier, NCT03228420. Competing Interests: Declaration of competing interest Author Erika A. Petersen has received consulting fees from Abbott Laboratories, Biotronik, Boston Scientific, Medtronic Neuromodulation, Nalu Medical, Neuros Medical, Nevro Corp, Presidio Medical, Saluda, and Vertos Medical, research support from Mainstay, Medtronic Neuromodulation, Nalu Medical, Neuros Medical, Nevro Corp, ReNeuron, Saluda, and SPR, and stock options from neuro42 and SynerFuse. Author Thomas G. Stauss has received research support from Nevro Corp. Author James A. Scowcroft has received research support from Boston Scientific, Nevro Corp, Saluda Medical, and Vertiflex. Author Michael J. Jaasma is an employee of Nevro Corp. Author Elizabeth S. Brooks was an employee of Nevro Corp during her contributions to the work associated with this manuscript. Author Deborah R. Edgar received consulting fees from Nevro in her capacity as an independent medical writer. Author Judith L. White has received consulting fees from California Institute for Biomedical Research and Eli Lilly and research support from Nevro Corp. Author Shawn M. Sills has received research support from Nevro Corp. Author Kasra Amirdelfan has received consulting fees from Biotronik, Medtronic, Nalu Medical, Nevro Corp, and Saluda Medical, as well as research support from Biotronik, IPM Medical Group, Nevro Corp, Saluda Medical, SPR Therapeutics, and Vivex Biologics. Author Maged N. Guirguis has received consulting fees from Abbott Laboratories, Avanos Medical, Avertis Pharmacy, Boston Scientific, Nevro Corp, and Saluda Medical, as well as research support from Abbott Laboratories, Avanos Medical, Boston Scientific, Nalu Medical, Neuros Medical, Nevro Corp, and Saluda Medical. Author Jijun Xu has received research support from the Cleveland Clinic Velosano Program, the National Institutes of Health, the Steve and Melody Golding Foundation, and Nevro Corp. Author Cong Yu has received research support from Nevro Corp. Author Ali Nairizi has received consulting fees from Aurora Spine, Flowonix, and Nevro Corp as well as research support from Nevro Corp. Author Denis G. Patterson has received consulting fees from Abbott Laboratories, AIS Healthcare, Allergan, Amgen, Aurora Spine, CornerLoc, Flowonix, Lundbeck, Pajunk Medical, Saluda Medical, Spark Biomedical, and Vertos Medical, research support from Abbott Laboratories, Aurora Spine, Flowonix, Nevro Corp, and Saluda Medical, speakers’ bureau or honoraria from Abbott Laboratories, Allergan, Amgen, CornerLoc, Lundbeck, Saluda Medical, and Vertos Medical, and stock options from CornerLoc. Author Michael J. Creamer has received research support from Nevro Corp. Author Vincent Galan has received research support from Biotronik, Medtronic, Nevro Corp, PainTEQ, SPR Therapeutics, and St. Jude. Author Richard H. Bundschu has received research support from Nevro Corp. Author Neel D. Mehta has received consulting fees from Averitas, Nevro Corp, and Salix Pharmaceuticals, as well as research support from Boston Scientific and Nevro Corp. Author Dawood Sayed has received consulting fees from Abbott Laboratories, Boston Scientific, Flowonix, Medtronic, Nevro Corp, Vertiflex, and Vertos Medical, as well as research support from Abbott Laboratories, Biotronic, Nevro Corp, Vertiflex, and Vertos Medical. Author Shivanand P. Lad has received consulting fees from Nevro Corp and research support from Nevro Corp. Author David J. DiBenedetto has received research support from Nevro Corp, as well as funding for serving as principal investigator of a study supported by SPR Therapeutics paid to his institution. Author Khalid A. Sethi has received research support from Nevro Corp. Author Johnathan H. Goree has received consulting fees from Abbott Laboratories and Stratus Medical. Author Paul W. Wu has received research support from Nevro Corp. Author Charles E. Argoff has received consulting fees from AbbVie, Amgen, Biohaven, Clexio Biosciences, Collegium, Eli Lilly, Elsevier, Flowonix, Gene Pharma, Lundbeck, Nevro Corp, Novartis, Pfizer, SK Life Science, Teva Pharmaceutical, and Vertex as well as research support from AbbVie, Allergan, Amgen, Daiichi Sankyo, Eli Lilly, Novartis, Teva Pharmaceutical, and Vertex Pharmaceuticals. Author Christian E. Nasr has received consulting fees from Exelixis, Neurogastrx, and Nevro Corp as well as research support from Nevro Corp. Author Rod S. Taylor has received consulting fees from Nevro Corp, Medtronic, and Saluda Medical. Author David L. Caraway is an employee of Nevro Corp. Author Nagy A. Mekhail has received consulting fees from Nevro Corp, Relievant Medsystems, Saluda Medical, Sollis Therapeutics, and Vertos Medical, as well as research support from Avanos Medical, Mesoblast, Neuros Medical, and Nevro Corp. (Copyright © 2023. Published by Elsevier B.V.) |
| References: | Neuromodulation. 2020 Jul;23(5):673-679. (PMID: 31429165) Diabetes Care. 2014 Nov;37(11):3016-24. (PMID: 25216508) Psychol Med. 1988 Nov;18(4):1007-19. (PMID: 3078045) PLoS One. 2016 Apr 27;11(4):e0154654. (PMID: 27119372) Pain. 2014 Nov;155(11):2426-31. (PMID: 25180016) Spine (Phila Pa 1976). 1996 Dec 1;21(23):2786-94. (PMID: 8979327) Biomedicines. 2022 Oct 19;10(10):. (PMID: 36289892) Neurol Clin Pract. 2020 Feb;10(1):47-57. (PMID: 32190420) Pain Med. 2015 Mar;16(3):520-30. (PMID: 25530081) Pain. 2008 Jul 15;137(2):276-285. (PMID: 17937976) Mayo Clin Proc Innov Qual Outcomes. 2022 Jul 01;6(4):347-360. (PMID: 35814185) Sci Rep. 2023 Mar 21;13(1):4591. (PMID: 36944694) Diabetes Care. 2015 Sep;38(9):e132-4. (PMID: 26116722) Cochrane Database Syst Rev. 2017 Jun 09;6:CD007938. (PMID: 28597471) Pain Res Manag. 2012 Jul-Aug;17(4):281-90. (PMID: 22891194) Cochrane Database Syst Rev. 2014 Jan 03;(1):CD007115. (PMID: 24385423) Pain Med. 2001 Dec;2(4):309-16. (PMID: 15102235) Pain Pract. 2018 Apr;18(4):500-504. (PMID: 28875558) Endocr Pract. 2022 Oct;28(10):923-1049. (PMID: 35963508) Pharmacol Ther. 2021 Apr;220:107743. (PMID: 33181192) Pain Med. 2023 Oct 13;24(Supplement_2):S33-S40. (PMID: 37833050) J Neurosurg. 2008 Feb;108(2):292-8. (PMID: 18240925) Curr Diab Rep. 2019 Aug 27;19(10):86. (PMID: 31456118) Pain Med. 2015 Nov;16(11):2075-83. (PMID: 26118704) Anesthesiology. 2015 Oct;123(4):851-60. (PMID: 26218762) Biomedicines. 2022 Feb 20;10(2):. (PMID: 35203706) Int Wound J. 2019 Dec;16(6):1373-1382. (PMID: 31489774) Qual Life Res. 2011 Dec;20(10):1727-36. (PMID: 21479777) Cochrane Database Syst Rev. 2019 Jan 23;1:CD007076. (PMID: 30673120) Pain. 1994 Feb;56(2):211-216. (PMID: 8008410) Value Health. 2018 Sep;21(9):1090-1097. (PMID: 30224114) JAMA Neurol. 2021 Jun 1;78(6):687-698. (PMID: 33818600) Diabetes Res Clin Pract. 2015 Aug;109(2):215-25. (PMID: 26008721) Curr Diab Rep. 2019 May 7;19(6):32. (PMID: 31065863) Pain. 2005 Mar;114(1-2):29-36. (PMID: 15733628) Trials. 2020 Jan 15;21(1):87. (PMID: 31941531) Diabetes Care. 2022 Jan 1;45(1):e3-e6. (PMID: 34844993) Health Qual Life Outcomes. 2013 Jan 18;11:8. (PMID: 23332037) Neuromodulation. 2015 Oct;18(7):603-8; discussion 608-9. (PMID: 26053499) Neuromodulation. 2011 Jul-Aug;14(4):312-8; discussion 318. (PMID: 21992424) Pain Med. 2016 Feb;17(2):325-36. (PMID: 26814260) Clin Endocrinol (Oxf). 2012 Jul;77(1):51-5. (PMID: 21906118) Neuromodulation. 2017 Aug;20(6):543-552. (PMID: 28714533) Pain. 2018 Nov;159(11):2339-2346. (PMID: 30015707) Neurosurgery. 2006 Mar;58(3):481-96; discussion 481-96. (PMID: 16528188) Neuromodulation. 2017 Oct;20(7):642-649. (PMID: 28834092) Diabetes Care. 2018 Jan;41(1):32-38. (PMID: 29109298) J Pain Res. 2023 May 18;16:1607-1636. (PMID: 37229154) Neurosurgery. 1993 Mar;32(3):384-94; discussion 394-5. (PMID: 8455763) Lancet Neurol. 2015 Feb;14(2):162-73. (PMID: 25575710) |
| معلومات مُعتمدة: | K08 CA228039 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: Diabetes mellitus; Neuropathy; Painful diabetic neuropathy; Sensory function; Spinal cord stimulation |
| سلسلة جزيئية: | ClinicalTrials.gov NCT03228420 |
| تواريخ الأحداث: | Date Created: 20230803 Date Completed: 20231116 Latest Revision: 20240123 |
| رمز التحديث: | 20240123 |
| مُعرف محوري في PubMed: | PMC10801706 |
| DOI: | 10.1016/j.diabres.2023.110865 |
| PMID: | 37536514 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder كن أول من يترك تعليقا!